Table 2.
Acute adverse events regardless of attribution (CTCAE v4.0)
| Adverse Event | Conventional (N=41) | Hypofractionation (N=41) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Total | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Total | |
| Breast infection | 1 (2.4%) | 1 (2.4%) | 2 (4.9%) | 3 (7.3%) | 3 (7.3%) | |||||||
| Esophagitis | 5 (12.2%) | 5 (12.2%) | 6 (14.6%) | 2 (4.9%) | 8 (19.5%) | |||||||
| Breast edema | 9 (22.0%) | 9 (22.0%) | 4 (9.8%) | 4 (9.8%) | ||||||||
| Skin hyperpigmentation | 30 (73.2%) | 2 (4.9%) | 32 (78.0%) | 19 (46.3%) | 2 (4.9%) | 21 (51.2%) | ||||||
| Edema limbs | 5 (12.2%) | 5 (12.2%) | 1 (2.4%) | 1 (2.4%) | 2 (4.9%) | |||||||
| Dermatitis radiation | 20 (48.8%) | 19 (46.3%) | 39 (95.1%) | 33 (80.5%) | 7 (17.1%) | 40 (97.6%) | ||||||
| Stroke | 1 (2.4%) | 1 (2.4%) | ||||||||||
| Non-cardiac chest pain | 2 (4.9%) | 2 (4.9%) | 2 (4.9%) | 2 (4.9%) | ||||||||
| Joint range of motion decreased | 11 (26.8%) | 11 (26.8%) | 7 (17.1%) | 7 (17.1%) | ||||||||
Adverse events of grade 1–2 occurring in at least 10% of patients or grade 3–5 occurring in any patient across both groups are reported. Note: No grade 4 events were reported in either arm and no grade 5 events in the conventional arm